Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple myeloma and chronic lymphocytic leukemia. Testing for minimal residual ...

CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year. Key drivers included a higher gapfill rate of $2,007 for the clonoSEQ test ...

An innovative approach could transform the treatment landscape for DLBCL patients, offering hope to those who might otherwise ...

Foundation Medicine adds a tissue-informed whole genome sequencing molecular residual disease test to its portfolio of high-quality testing solutions.

SEATTLE, July 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...

Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences. Video Player is loading.

DUBLIN--(BUSINESS WIRE)--The "Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis By Offering, Technology, Application Sample - Global Forecast to 2031" report has been ...

Personalis has high upside potential if its MRD test gains Medicare reimbursement, but current revenue and margins are under pressure. The company faces declining pharma revenue, sustained cash burn, ...

CHICAGO — In this video, Sandra Mazzoni, DO, discusses the use of minimal residual disease, or MRD, testing in multiple myeloma. “There’s a lot of hot topics right now in myeloma in general,” Mazzoni, ...

Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data ...

In this installment of Chief Insights in Oncology, John M. Burke, MD, co-editor in chief of Targeted Therapies in Oncology, discusses his column from the September II 2025 issue.